News

Biopharma news, November 6, 2026

The most important drug and company news of November 6, 2026, ranked, each linked to its Gosset profiles.

  1. Approval

    Pfizer's Hympavzi approved in China for hemophilia patients with inhibitors

    China extended Hympavzi, Pfizer's weekly subcutaneous anti-TFPI antibody, to routine prophylaxis in people aged 12 and up weighing at least 35 kg with hemophilia A or B and factor inhibitors. In the BASIS phase 3 trial, treated bleeds fell an estimated 93% versus on-demand bypassing agents, and 94.3% of patients cleared all baseline target joints within a year.

    Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

  2. Approval

    FDA grants accelerated approval to subcutaneous amivantamab in head and neck cancer

    Johnson & Johnson's Rybrevant Faspro won US accelerated approval as a single agent for head and neck squamous cancer that has recurred or spread after platinum chemotherapy and a PD-(L)1 antibody, excluding HPV-linked oropharyngeal tumours. In the OrigAMI-4 cohort of 102 patients, 42% responded. Serious adverse reactions hit 39%, and full approval may hinge on the OrigAMI-5 trial.

    Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

  3. Approval

    EU adds axial spondyloarthritis to Alfasigma's Jyseleca label

    The European Commission cleared filgotinib for adults with axial spondyloarthritis, in either its radiographic or non-radiographic form, after inadequate response to conventional care. Across the OLINGUITO phase 3 program, more patients reached ASAS40 at week 16 on the JAK1-preferring drug than on placebo, with gains holding to week 52. A UK filing is pending.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  4. Approval

    UK extends Joenja to APDS patients as young as four

    The MHRA extended Pharming Group's leniolisib to children with activated PI3K delta syndrome who weigh 27 kg or more, making it the first UK therapy aimed at this young group. The label adds twice-daily 40 mg and 50 mg doses. Pharming expects children to gain access in February 2027 and will work with the NHS on supply.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  5. Licensing & partnership

    Funnel Biosciences signs AI antibody pact with Third Rock worth up to $2.16B

    Funnel Biosciences will apply its epitope-guided AI antibody design platform to several targets chosen by Third Rock Ventures. Funnel gets platform fees and could earn up to about $2.16 billion if set conditions are met; the split of payments was not disclosed. The company claims its system yields picomolar binders without lab affinity maturation.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

  6. Pivotal readout

    Seladelpar normalizes ALP in most PBC patients in phase 3 IDEAL trial

    Gilead reported that 75.4% of people taking Livdelzi reached the week-52 composite of normal alkaline phosphatase plus a 15% drop, against 16.1% on placebo, in a 96-person trial. Participants had primary biliary cholangitis with only mildly raised ALP despite or without tolerating ursodeoxycholic acid. No new safety signals emerged; regulators will be consulted.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  7. Approval

    China approves Bayer's HER2 inhibitor for first-line HER2-mutant lung cancer

    Bayer's oral HER2 tyrosine kinase inhibitor, already cleared in China after prior therapy, is now approved as monotherapy for untreated advanced lung cancer carrying HER2 mutations. In 73 treatment-naive patients from the SOHO-01 study, 75.3% responded and 72.7% of responders stayed in response for six months or more.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

  8. Pivotal readout

    TQ-B3139 keeps PFS lead over crizotinib in final ALK-positive lung cancer analysis

    Final results from the 264-patient TQ-B3139-III-01 phase 3 study were published after about 46 months of follow-up. Investigator-assessed median progression-free survival was 30.4 months with TQ-B3139 versus 12.0 months with crizotinib as first treatment for advanced ALK-positive lung cancer. The drug has been approved in China for this setting since June 2024.

    Source types: News article. Sources are available to Gosset users. Log in to see them.

  9. Financing

    INOVIO prices a $75 million stock and warrant offering

    DNA-medicine developer INOVIO set the price of an underwritten offering of common shares at $1.05 each, alongside pre-funded warrants, for gross proceeds of about $75 million. Closing is expected around November 9, and underwriters can buy roughly 10.7 million more shares within 30 days.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

  10. Clinical readout

    Evaxion's EVX-01 cancer vaccine shows broad T-cell responses in phase 2 melanoma data

    New biomarker results from the phase 2 study of the personalized vaccine EVX-01 in advanced melanoma found that most chosen vaccine targets triggered tumour-specific immunity, and CD8 responses appeared in half of patients. After two years, 12 of 16 patients had responded, four of them completely. Patients began treatment with EVX-01 plus Keytruda.

    Source types: Press release. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call